Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · mng-umap@100

MNG163

—

2d9c7cfa-773d-5488-a72a-62905e3d4fd0

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • MYC_TARGETS_V2+0.519
  • MYC_TARGETS_V1+0.369
  • G2M_CHECKPOINT+0.366
  • INTERFERON_ALPHA_RESPONSE+0.365
  • MITOTIC_SPINDLE+0.360
  • E2F_TARGETS+0.358
  • UNFOLDED_PROTEIN_RESPONSE+0.302
  • WNT_BETA_CATENIN_SIGNALING+0.267
  • GLYCOLYSIS+0.222
  • HEDGEHOG_SIGNALING+0.192

Top 10 suppressed

  • KRAS_SIGNALING_UP-0.228
  • ALLOGRAFT_REJECTION-0.226
  • TGF_BETA_SIGNALING-0.201
  • COMPLEMENT-0.197
  • COAGULATION-0.184
  • OXIDATIVE_PHOSPHORYLATION-0.168
  • REACTIVE_OXYGEN_SPECIES_PATHWAY-0.130
  • INFLAMMATORY_RESPONSE-0.122
  • SPERMATOGENESIS-0.121
  • FATTY_ACID_METABOLISM-0.120

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-34-5929-01A-11R-1820-07
lung-landscapes@6
—cohortSQ10.809
2MNG387
mng-umap@100
——0.807
3MNG1064
mng-umap@100
——0.763
4TCGA-51-6867-01A-11R-2045-07
lung-landscapes@6
—cohortSQ20.740
5TCGA-56-A62T-01A-11R-A405-07
lung-landscapes@6
—cohortSQ10.739
6MNG979
mng-umap@100
——0.732
7SRR8518200
breast-umap@18
—E0.730
8MNG162
mng-umap@100
——0.727
9TCGA-CR-6493-01A-11R-1873-07
head-neck@1
——0.721
10TCGA-77-8009-01A-11R-2187-07
lung-landscapes@6
—cohortSQ20.719

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 24 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
MYC_TARGETS_V20.519Idelalisib— uncovered
MYC_TARGETS_V10.369Inavolisib— uncovered
G2M_CHECKPOINT0.366Inavolisib— uncovered
INTERFERON_ALPHA_RESPONSE0.365Inavolisib— uncovered
MITOTIC_SPINDLE0.360Inavolisib— uncovered
E2F_TARGETS0.358Inavolisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.302Idelalisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.267Inavolisib— uncovered
GLYCOLYSIS0.222Inavolisib— uncovered
HEDGEHOG_SIGNALING0.192Inavolisib— uncovered
ANGIOGENESIS0.189Remibrutinib— uncovered
MTORC1_SIGNALING0.188Inavolisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.144Inavolisib— uncovered
APICAL_SURFACE0.128Temsirolimus— uncovered
DNA_REPAIR0.128Idelalisib— uncovered
INTERFERON_GAMMA_RESPONSE0.127Idelalisib— uncovered
ESTROGEN_RESPONSE_EARLY0.126Inavolisib— uncovered
PANCREAS_BETA_CELLS0.121Cobimetinib— uncovered
APICAL_JUNCTION0.113Inavolisib— uncovered
PROTEIN_SECRETION0.099Remibrutinib— uncovered